Rheumatoid arthritis increases the risk of malignant neoplasm of bone and articular cartilage: a two-sample bidirectional mendelian randomization study.


Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
13 11 2023
Historique:
received: 03 09 2023
accepted: 03 11 2023
medline: 15 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

Prior research has revealed a heightened prevalence of neoplasms in individuals diagnosed with rheumatoid arthritis (RA). The primary objective of this study is to delve into the causal association between RA and two distinct types of neoplasms: benign neoplasm of bone and articular cartilage (BNBAC) and malignant neoplasm of bone and articular cartilage (MNBAC). We employed summary data from genome-wide association analyses (GWAS) to investigate the causal relationship between RA and two neoplasms, BNBAC and MNBAC, using a two-sample bidirectional Mendelian randomization (MR) study design. The IEU OpenGWAS database provided the GWAS summary data for RA, while the Finnish consortium supplied the GWAS summary data for BNBAC and MNBAC. Our analysis involved the utilization of eight distinct MR methods, namely random-effects inverse variance weighted (IVW), MR Egger, weighted median, simple mode, weighted mode, maximum likelihood, penalized weighted median, and fixed effects IVW. Subsequently, we conducted assessments to evaluate heterogeneity, horizontal pleiotropy, outliers, the impact of a single-nucleotide polymorphism (SNP), and adherence to the assumption of normal distribution in the MR analysis. The results from the MR analysis revealed that there was no significant genetic association between RA and BNBAC (P = 0.427, odds ratio [OR] 95% confidence interval [CI] = 0.971 [0.904-1.044]). However, a positive genetic association was observed between RA and MNBAC (P = 0.001, OR 95% CI = 1.413 [1.144-1.745]). Conducting a reverse MR analysis, we found no evidence to support a genetic causality between BNBAC (P = 0.088, OR 95% CI = 1.041 [0.994-1.091]) or MNBAC (P = 0.168, OR 95% CI = 1.013 [0.995-1.031]) and RA. Our MR analysis demonstrated the absence of heterogeneity, horizontal pleiotropy, and outliers and confirmed that the effect was not driven by a single SNP. Additionally, the data exhibited a normal distribution. The findings of this study demonstrate that RA constitutes a significant risk factor for MNBAC. In the context of clinical application, it is advisable to conduct MNBAC screening in RA patients and remain vigilant regarding its potential manifestation. Importantly, the outcomes of this investigation introduce a fresh vantage point into the understanding of the tumorigenesis associated with RA.

Identifiants

pubmed: 37957703
doi: 10.1186/s13075-023-03205-5
pii: 10.1186/s13075-023-03205-5
pmc: PMC10642064
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

219

Informations de copyright

© 2023. The Author(s).

Références

Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5
pubmed: 20943636
Rheumatology (Oxford). 2021 Feb 1;60(2):940-946
pubmed: 32944772
J Inflamm Res. 2022 Feb 15;15:977-986
pubmed: 35210806
Arthritis Rheumatol. 2017 Apr;69(4):700-708
pubmed: 27992692
Front Aging Neurosci. 2022 Mar 04;13:793023
pubmed: 35317304
Int J Epidemiol. 2014 Feb;43(1):224-34
pubmed: 24425828
Sao Paulo Med J. 2005 Jan 2;123(1):21-3
pubmed: 15821811
Lancet Oncol. 2010 Feb;11(2):184-92
pubmed: 20152770
J Pediatr. 1999 Jan;134(1):53-7
pubmed: 9880449
Pain. 2013 Dec;154 Suppl 1:S54-S62
pubmed: 23916671
Front Nutr. 2023 Mar 23;10:1047640
pubmed: 37032771
Front Pharmacol. 2022 Mar 02;13:768980
pubmed: 35308252
J Clin Med. 2023 Feb 02;12(3):
pubmed: 36769847
Ann Med. 2022 Dec;54(1):1636-1645
pubmed: 35703935
Hum Immunol. 2022 Jan;83(1):81-85
pubmed: 34521568
Autoimmun Rev. 2021 May;20(5):102797
pubmed: 33746022
Rheumatology (Oxford). 2007 Jan;46(1):1-2
pubmed: 16936333
J Autoimmun. 2020 Jun;110:102400
pubmed: 31980337
Biomed Pharmacother. 2018 Jun;102:894-911
pubmed: 29710545
Rheum Dis Clin North Am. 2020 Aug;46(3):445-462
pubmed: 32631599
Biomed Res Int. 2013;2013:748178
pubmed: 24151619
BMJ Open Diabetes Res Care. 2020 Dec;8(2):
pubmed: 33293297
Elife. 2018 May 30;7:
pubmed: 29846171
Rheumatology (Oxford). 2020 Oct 1;59(10):2661-2670
pubmed: 32638005
Nutrients. 2023 Feb 20;15(4):
pubmed: 36839415
Hematol Oncol. 2018 Dec;36(5):733-739
pubmed: 29862535
JAMA. 2006 May 17;295(19):2275-85
pubmed: 16705109
Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16
pubmed: 30596879
Arthritis Rheumatol. 2023 Nov;75(11):2027-2035
pubmed: 37219954
Ann Rheum Dis. 2021 May;80(5):558-565
pubmed: 33310728
Inflamm Regen. 2020 Sep 7;40:20
pubmed: 32944095
Curr Opin Pediatr. 2009 Jun;21(3):365-72
pubmed: 19421061
Nutrients. 2022 Mar 22;14(7):
pubmed: 35405941
Adv Anat Pathol. 2021 May 1;28(3):119-138
pubmed: 33480599
Future Oncol. 2020 Mar;16(9):483-495
pubmed: 32100561
Front Genet. 2021 Jul 26;12:686939
pubmed: 34381493
Semin Immunopathol. 2022 Jan;44(1):47-62
pubmed: 35088123

Auteurs

Mingyi Yang (M)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Yani Su (Y)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Ke Xu (K)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Jiale Xie (J)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Pengfei Wen (P)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Lin Liu (L)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Zhi Yang (Z)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Peng Xu (P)

Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China. sousou369@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH